Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Under The Microscope: Indian Pharmaceutical Acquisitions

By Pharmaceutical Processing | May 26, 2010

Branded pharmaceutical companies establishing beachheads in India is a logical choice as they see access to a market to growing at 10+ percent. India is a source of revenue and profit replenishment for these multinational firms. The end result of such acquisitions is going to be higher drug prices for the masses – or government intervention. It’s going to be interesting to see what develops.

However, there is an underlying question about the sale of Indian pharmaceutical companies. Why?

Since 2005 Indian companies have challenged the multinationals and have forced a landscape change. Why are these companies being sold now when they have created very successful franchises? One could say the price was too good to refuse. May be, but has anyone considered another reason i.e. lack of succession in the entrepreneur families or letting trained managers run and grow the companies to compete with the brand companies.

The Singh family (Ranbaxy) allegedly had a family feud and they brought in Dr. Brian Tempest to cool the storm. However, under the Singh family regime there were quality lapses as manifested by the US FDA’s actions. Were these lapses beyond the company’s control to fix? Under these circumstances the Singh family got an offer they could not refuse. Could that be the case with the Piramal family?

Consolidation within India i.e. one successful company buying another pharmaceutical company is not in the culture. Thus, unless there is strong succession planning, we will see repeats of Matrix Labs, Ranbaxy, Shantha Biotech and most recently Piramal Healthcare.

If the entrepreneur families do not pass the baton to trained professionals, I believe Indian pharmaceutical manufacturers, API (active pharmaceutical ingredient) companies, formulators and others associated with the Indian pharmaceutical industry will be selling out to multi-national corporations. It will be a case of take your money and run.

 

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE